Moving forward, slowly but surely

Nature Reviews Nephrology

Volumn 9, Issue 2, 2013, Pages 69-70

  Garimella, Pranav S ^a   Sarnak, Mark J ^a  

^a TUFTS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; CINACALCET; CREATININE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; SODIUM; WARFARIN;

BLEEDING; BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CHRONIC KIDNEY DISEASE; COMPARATIVE STUDY; CREATININE URINE LEVEL; DIALYSIS; DISEASE ASSOCIATION; GLOMERULUS FILTRATION RATE; HEART ATRIUM FIBRILLATION; HEMODIALYSIS PATIENT; HUMAN; INTERNATIONAL NORMALIZED RATIO; KIDNEY FAILURE; OBSERVATIONAL STUDY; PRIORITY JOURNAL; PROTEINURIA; RISK FACTOR; SHORT SURVEY; SODIUM RESTRICTION; SODIUM URINE LEVEL; SYSTOLIC BLOOD PRESSURE; CHRONIC KIDNEY FAILURE; COMORBIDITY; INCIDENCE; PATHOPHYSIOLOGY; REVIEW;

CARDIOVASCULAR DISEASES; COMORBIDITY; HUMANS; INCIDENCE; RENAL INSUFFICIENCY, CHRONIC; RISK FACTORS;

MLCS; MLOWN;

EID: 84873193475     PISSN: 17595061     EISSN: 1759507X     Source Type: Journal    
DOI: 10.1038/nrneph.2012.285     Document Type: Short Survey

References (10)

1. Sarnak, M. J. et al. Kidney disease as a risk factor for development of cardiovascular disease: A statement from the American Heart Association Councils on Kidney in Cardiovascular Disease, High Blood Pressure Research, Clinical Cardiology, and Epidemiology and Prevention. Circulation 108, 2154-2169 (2003).
2. Tonelli, M. et al. Risk of coronary events in people with chronic kidney disease compared with those with diabetes: A population-level cohort study. Lancet 380, 807-814 (2012).
3. Lambers Heerspink, H. J. et al. Moderation of dietary sodium potentiates the renal and cardiovascular protective effects of angiotensin receptor blockers. Kidney Int. 82, 330-337 (2012).
4. Vegter, S. et al. Sodium intake, ACE inhibition, and progression to ESRD. J. Am. Soc. Nephrol. 23, 165-173 (2012).
5. O'Donnell, M. J. et al. Urinary sodium and potassium excretion and risk of cardiovascular events. JAMA 306, 2229-2238 (2012).
6. Olesen, J. B. et al. Stroke and bleeding in atrial fibrillation with chronic kidney disease. N. Engl. J. Med. 367, 625-635 (2012).
7. Chan, K. E., Lazarus, J. M., Thadhani, R. & Hakim, R. M. Warfarin use associates with increased risk for stroke in hemodialysis patients with atrial fibrillation. J. Am. Soc. Nephrol. 20, 2223-2233 (2009).
8. Thadhani, R. et al. Vitamin D therapy and cardiac structure and function in patients with chronic kidney disease: The PRIMO randomized controlled trial. JAMA 307, 674-684 (2012).
9. The EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N. Engl. J. Med. http://dx.doi.org/10. 1056/NEJMoa1205624.
10. US Renal Data System. USRDS 2012 Annual Data Report: Atlas of Chronic Kidney Disease and End-Stage Renal Disease in the United States [online], http://www.usrds.org/adr.aspx (2012).